(NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the ...

What's more, DB-5ms delivers excellent inertness with active compounds. These columns are exact replacements for HP-5TA, and are close equivalents to USP phase G27. DB-5ms is very low bleed ...